Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole as potential inhibitors of hepatitis C virus

Open access

Abstract

New derivatives of 2-thiobenzimidazole incorporating triazole moiety were synthesized, characterized and tested in vitro for antiviral activity against hepatitis C virus (HCV) and hepatitis B virus (HBV). Their cytotoxicity was determined by the reduction in the number of viable cell. All of the synthesized compounds are inactive against HBV and some showed activity against HCV. In particular, two compounds showed significant activity, 2-{4-[(1-benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitro-phenyl)-acetamide (13) and 2-(4-{[1-(p-chlorobenzoyl)-benzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide (17). The results give an insight into the importance of the substituent at position 2 of benzimidazole for the inhibition of HCV.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. J. S. Au and P. J. Pockros Novel therapeutic approaches for hepatitis C Clin. Pharmacol. Ther. 95 (2014) 78–88; DOI: 10.1038/clpt.2013.206.

  • 2. M. P. Manns J. G. McHutchison S. C. Gordon V. K. Rustgi M. Shiffman R. Reindollar Z. D. Goodman K. Koury M. Ling and J. K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 (2001) 958–965.

  • 3. M. W. Fried M. L. Shiffman K. R. Reddy C. Smith G. Marinos F. L. Gonçales Jr. D. Häussinger M. Diago G. Carosi D. Dhumeaux A. Craxi A. Lin J. Hoffman and J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 (2002) 975–982; DOI: 10.1056/NEJMoa020047.

  • 4. Y. Bansal and O. Silakari The therapeutic journey of benzimidazoles: A review Bioorg. Med. Chem. 20 (2012) 6208–6236; DOI: 10.1016/j.bmc.2012.09.013.

  • 5. V. Boido G. Paglietti M. Tonelli and G. Vitale Non-nucleoside Benzimidazoles as Antiviral Drugs Against HCV and RSV Infections in RNA-Viruses. Enzymatic and Receptoral Inhibitors (Ed. A. Carta) Research Signpost Kerala 2009 pp. 41–93.

  • 6. B. A. Katz J. Clark J. Finer-Moore T. Jenkins C. Johnson M. Ross C. Luong W. Moore and R. Stroud Design of potent selective zinc-mediated serine protease inhibitors Nature 391 (1998) 608–612; DOI: 10.1038/35422.

  • 7. D. Sperandio A. R. Gangloff J. Litvak R. Goldsmith J. M. Hataye V. R. Wang E. J. Shelton K. Elrod J. W. Janc J. M. Clark K. Rice S. Weinheimer K. Yeung N. A. Meanwell D. Hernandez A. J. Staab B. L. Venables and J. R. Spencer Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease Bioorg. Med. Chem. Lett. 12 (2002) 3129–3133; DOI: 10.1016/S0960-894X(02)00680-7.

  • 8. H. I. El Diwani H. T. Abdel-Mohsen I. Salama F. A.-F. Ragab M. M. Ramla S. A. Galal M. M. Abdalla A. Abdel-Wahab and M. A. El Demellawy Synthesis molecular modeling and biological evaluation of novel benzimidazole derivatives as inhibitors of hepatitis C virus RNA replication Chem. Pharm. Bull. 62 (2014) 856–866; DOI: 10.1248/cpb.c13-01009.

  • 9. L. Garuti M. Roberti and G. Gentilomi Synthesis and antiviral assays of some 2-substituted benzimidazole-N-carbamates Farmaco 55 (2000) 35–39; DOI: 10.1016/S0014-827X(99)00117-2.

  • 10. S. Budow M. Kozlowska A. Gorska Z. Kazimierczuk H. Eickmeier P. La Colla G. Gosselin and F. Seela Substituted benzimidazole: antivral activity and synthesis of nucleosides ARKIVOC iii (2009) 225–250; DOI: 10.3998/ark.5550190.0010.319.

  • 11. M. F. Tonelli F. Novelli B. Tasso I. Vazzana A. Sparatore V. Boido F. Sparatore P. La Colla G. Sanna G. Giliberti B. Busonera P. Farci C. Ibba and R. Loddo Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5 anti-RSV and anti-Sb-1 agents Bioorg. Med. Chem. 22 (2014) 4893–4909; DOI: 10.1016/j.bmc.2014.06.043.

  • 12. Y. Saito V. Escuret D. Durantel F. Zoulim R. F. Schinazic and L. A. Agrofoglio Synthesis of 123-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon Bioorg. Med. Chem. 11 (2003) 3633–3639; DOI: 10.1016/S0968-0896(03)00349-3.

  • 13. F. D. Da Silva M. C. B. V. de Souza I. I. P. Frugulhetti H. C. Castro S. L. D Souza T. M. L. de Souza D. Q. Rodrigues A. M. T. Souza P. A. Abreu F. Passamani C. R. Rodrigues and V. F. Ferreira Synthesis HIV-RT inhibitory activity and SAR of 1-benzyl-1H-123-triazole derivatives of carbohydrates Eur. J. Med. Chem. 44 (2009) 373–383; DOI: 10.1016/j.ejmech.2008.02.047.

  • 14. D. K. Mohapatra P. K. Maity M. Shabab and M. I. Khan Click chemistry based rapid one-pot synthesis and evaluation for protease inhibition of new tetracyclic triazole fused benzodiazepine derivatives Bioorg. Med. Chem. 19 (2009) 5241–5245; DOI: 10.1016/j.bmcl.2009.06.107.

  • 15. T. O. Olomola R. Klein K. A. Lobb Y. Sayed and P. T. Kaye Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors Bioorg. Med. Chem. 21 (2013) 1964–1971; DOI: 10.1016/j.bmc.2013.01.025.

  • 16. M. M. Heravi A. Keivanloo M. Rahimizadeh M. Bakavoli and M. Ghassemzadeh Pd–Cu catalyzed heterocyclization during Sonogashira coupling: synthesis of 3-benzylthiazolo[32-a]benzimidazole Tetrahedron Lett. 45 (2004) 5747–5749; DOI: 10.1016/j.tetlet.2004.05.094.

  • 17. K.-C. Tiew D. Dou T. Teramoto H. Lai K. R. Alliston G. H. Lushington R. Padmanabhan and W. C. Groutas Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d] isothiazol-3(2H)-one derivatives Bioorg. Med. Chem. 20 (2012) 1213–1221; DOI: 10.1016/j.bmc.2011.12.047.

  • 18. C. Baba K. Yanagida T. Kanzaki and M. Baba Colorimetric lactate dehydrogenase (LDH) assay for evaluation of antiviral activity against bovine viral diarrhoea virus (BVDV) in vitro Antivir. Chem. Chemother. 16 (2005) 33–39; DOI: 10.1016/j.biomaterials.2014.01.054.

  • 19. K. Sako H. Aoyama S. Sato Y. Hashimoto and M. Baba γ-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity Bioorg. Med. Chem. 16 (2008) 3780–3790; DOI: 10.1016/j.bmc.2008.01.052.

  • 20. H. C. Kolb M. G. Finn and K. B. Sharpless Click chemistry: Diverse chemical function from a few good reactions Angew. Chem. Int. Ed. 40 (2001) 2004–2021; DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5.

  • 21. J. E. Moses and A. D. Moorhouse The growing applications of click chemistry Chem. Soc. Rev. 36 (2007) 1249–1262; DOI: 10.1039/b613014n.

  • 22. S. G. Agalave S. R. Maujan and V. S. Pore Click chemistry: 123-Triazoles as pharmacophores Chem. Asian J. 6 (2011) 2696–2718; DOI: 10.1002/asia.201100432.

  • 23. J.-F. Lutz and Z. Zarafshani Efficient construction of therapeutics bioconjugates biomaterials and bioactive surfaces using azide-alkyne “click” chemistry Adv. Drug Deliv. Rev. 60 (2008) 958–970; DOI: 10.1016/j.addr.2008.02.004.

  • 24. K. Lin R. B. Perni A. D. Kwong and c. Lin VX-950 a novel hepatitis C virus (HCV) NS3-4A protease inhibitor exhibits potent antiviral activities in HCV replicon cells Antimicrob. Agents. Cli. 50 (2006) 1813–1822; DOI: 10.1128/AAC.50.5.1813-1822.2006.

  • 25. J. G. Topliss Utilization of operational schemes for analog synthesis in drug design J. Med. Chem. 15 (1972) 1006–1011; DOI: 10.1021/jm00280a002.

  • 26. J. G. Topliss A manual method for applying the Hansch approach to drug design J. Med. Chem. 20 (1977) 463–469; DOI: 10.1021/jm00214a001.

Search
Journal information
Impact Factor

IMPACT FACTOR 2018: 1.405
5-year IMPACT FACTOR: 1.701

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.314
Source Normalized Impact per Paper (SNIP) 2018: 0.637

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 441 335 9
PDF Downloads 218 183 4